“Brain healing” is one of those phrases that can make smart people stop asking questions. We don’t. Today we put two compounds under a bright light and let the evidence, the mechanisms, and the missing pieces speak for themselves: Dihexa and Cerebrolysin. Both get framed online as tools for cognition, recovery, and neuroprotection, but they live in very different worlds when you look at data quality and real-world oversight.

We start with Dihexa, the synthetic compound often called a “synapse builder.” We walk through synaptogenesis, dendritic spines, and why Alzheimer’s researchers care so much about connectivity loss. Then we slow down and do the part most posts skip: what animal studies can show, what they can’t, and why “more connections” is not automatically a healthier brain. We also face the uncomfortable realities head-on: no completed controlled human clinical trials, uncertain sourcing in the research-chemical marketplace, and a mechanism tied to HGF c-Met signaling, a pathway deeply studied in cancer biology. We even cover a key 2025 retraction and what that does to the tidy mechanism story.

Then we pivot to Cerebrolysin, a porcine brain peptide mixture that has been used internationally for decades and studied in dozens of randomized controlled trials across traumatic brain injury, stroke recovery, and dementia. The results are substantial but mixed, including a Cochrane review that raises real doubts in stroke outcomes, plus trial-quality and funding concerns that belong in any honest review. We also highlight the most concrete safety note clinicians watch for: lowered seizure threshold in people prone to seizures.

If you want a smarter way to think about peptides, biohacking, and brain health, come listen, share it with a friend, and subscribe. If the show helps you, leave a review so more people learn to question the headline and go looking for the mechanism underneath it.

What happens when six women sit around a table—with no script, no rehearsed answers, and permission to talk about the things women are really thinking?

In this special roundtable episode of Serenity & Fire, we pulled up six chairs inside Panacea and let the conversation go wherever it needed to go.

We talk about the things women whisper to themselves…and to each other.

The things we question. The things we struggle with. The things we’re sometimes afraid to admit. The expectations placed on us, the expectations we place on ourselves, and the parts of being a woman that somehow still don’t get talked about enough.

There are different perspectives. Personal stories. Vulnerable moments. Plenty of laughter. And probably a few things that will make you think, “Oh my God—I thought I was the only one who thought that.”

This isn't an interview. It isn't a panel of perfectly packaged answers. And it definitely isn't scripted.
It's six women sitting around a table having the kind of deep, intimate, honest conversation we wanted more women to be having.

So pull up a chair. Because if you've ever wondered whether other women are thinking some of the same things you are…there's a seat at this table for you.

People talk about “brain peptides” like they’re interchangeable shortcuts to focus, memory, and neuroprotection. They’re not. Today I put two of the most commonly paired compounds, CMAX and C-Link, through the same Serenity and Fire checklist so we can separate mechanisms, human evidence, and marketing claims without losing the excitement of what neuroscience might unlock next.

CMAX pulls us into stroke recovery, neuroplasticity, and neurotrophic signaling like BDNF and NGF. We walk through what has actually been studied in humans, why that matters more than a flashy biomarker, and what early Alzheimer’s model findings do and do not prove about prevention. I also explain why “enhancement” is a different goal than “recovery,” and why the data for healthy-person cognitive boosting is much thinner than the stories online.

C-Link comes in through anxiety and stress regulation, with a fascinating angle on GABA-related signaling that may reduce anxiety without simply sedating the brain. We zoom out to the biology of chronic stress, how it can hijack attention and memory, and why “thinking better” may sometimes mean turning down background noise. Then we get practical: intranasal delivery realities, sourcing and purity, long-term safety gaps, and FDA compounding concerns around C-Link acetate (TP7).

If you care about brain health, nootropics, biohacking, and longevity, hit play, then subscribe, leave a review, and share the episode with someone who’s trying to separate promise from proof.